Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Change In Receivables : $-28.44 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Tarsus Pharmaceuticals Change In Receivables?

Tarsus Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was $-13.65 Mil. It means Tarsus Pharmaceuticals's Accounts Receivable increased by $13.65 Mil from Dec. 2023 to Mar. 2024 .

Tarsus Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $-14.13 Mil. It means Tarsus Pharmaceuticals's Accounts Receivable increased by $14.13 Mil from Dec. 2022 to Dec. 2023 .

Tarsus Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was $29.89 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Tarsus Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 98.75.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Tarsus Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was $248.89 Mil.

Tarsus Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Tarsus Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tarsus Pharmaceuticals Change In Receivables Chart

Tarsus Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.03

0.02

-0.07

-3.49

-14.13

Tarsus Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															0.67	2.67	-6.12	-11.34	-13.65

Tarsus Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.44 Mil.

Tarsus Pharmaceuticals (NAS:TARS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Tarsus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	29.885	/	27.614	*	91
=	98.75

2. In Ben Graham's calculation of liquidation value, Tarsus Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Tarsus Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	298.524	-	74.067	+	0.75 * 29.885	+	0.5 * 4.036
=	248.89

Tarsus Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tarsus Pharmaceuticals Inc (NAS:TARS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618

Website

https://www.tarsusrx.com

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Executives

Bobak R. Azamian	director, 10 percent owner, officer: President and CEO	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Jose M. Trevejo	officer: Chief Medical Officer	C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Andrew D. Goldberg	director	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Dianne C. Whitfield	officer: Chief Human Resources Officer	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bryan Wahl	officer: General Counsel	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Elizabeth Yeu Lin	director	25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aziz Mottiwala	officer: Chief Commercial Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Jeffrey S Farrow	officer: See Remarks	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Leonard M. Greenstein	officer: Chief Financial Officer	24562 BELGREEN PLACE, LAKE FOREST CA 92630
Seshadri Neervannan	officer: Chief Operating Officer	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Mark J. Holdbrook	officer: V.P., Clinical Affairs	15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Michael Ackermann	director, 10 percent owner	202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Rosemary A Crane	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873